Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01385228 · ClinicalTrials.gov registry record · Phase 1
Pazopanib, Docetaxel, Prednisone Prostate
A Phase 1 study, sponsored by Daniel George, MD.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT01385228: Completed Phase 1 study, sponsored by Daniel George, MD.
NCT01385228 is a Phase 1 study that has completed, run by Daniel George, MD. The registered enrollment target is 36 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (40% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01385228, a Phase 1 study, has completed, sponsored by Daniel George, MD.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
The primary purpose is to define the safety and tolerability of docetaxel/prednisone in combination with pazopanib (DPP) in men with metastatic Castration Resistant Prostate Cancer (mCRPC).
Primary Outcome
The primary objective for the phase I study is to assess the safety and tolerability of pazopanib, docetaxel, and prednisone given in combination in patients with metastatic castration resistant prostate cancer.
Interventions
- DRUG Docetaxel
- DRUG Prednisone
- DRUG Pazopanib
- DRUG Pegfilgrastim
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2011-06 |
| Est. Completion | 2016-02 |
| Phase | Phase 1 |
What the finished NCT01385228 record still lists
NCT01385228 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (40% lower).
The record links to 0 conditions, and to 4 interventions - of which Docetaxel is the first listed.
NCT01385228 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01385228 about?
NCT01385228 is a clinical study titled "Pazopanib, Docetaxel, Prednisone Prostate". The primary purpose is to define the safety and tolerability of docetaxel/prednisone in combination with pazopanib (DPP) in men with metastatic Castration Resistant Prostate Cancer (mCRPC).
What is the current status of trial NCT01385228?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2011-06. Estimated completion is 2016-02.
What interventions are being tested in trial NCT01385228?
The interventions under investigation include: Docetaxel (DRUG), Prednisone (DRUG), Pazopanib (DRUG), Pegfilgrastim (DRUG).
Who is sponsoring clinical trial NCT01385228?
This trial is sponsored by Daniel George, MD, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01385228's enrollment target sits among peer trials
36 1210th of 2000 higher than 743 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia